I am a
Home I AM A Search Login

Papers of the Week


Papers: 30 Apr 2022 - 6 May 2022


Human Studies


2022 May 05


Cochrane Database Syst Rev


5

Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis.

Authors

Filippini G, Minozzi S, Borrelli F, Cinquini M, Dwan K
Cochrane Database Syst Rev. 2022 May 05; 5:CD013444.
PMID: 35510826.

Abstract

Spasticity and chronic neuropathic pain are common and serious symptoms in people with multiple sclerosis (MS). These symptoms increase with disease progression and lead to worsening disability, impaired activities of daily living and quality of life. Anti-spasticity medications and analgesics are of limited benefit or poorly tolerated. Cannabinoids may reduce spasticity and pain in people with MS. Demand for symptomatic treatment with cannabinoids is high. A thorough understanding of the current body of evidence regarding benefits and harms of these drugs is required.